RxDoctor Payments Data

Fang Ko, MD

Ophthalmology · Tallahassee, FLNPI 1205060290

Payments from drug & device makers

$36,300in general payments, 2019–2025

Across 231 payments — averaging $157.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$32K
  • AbbVie$1K
  • Alcon$720
  • Amgen$481
  • Aerie Pharmaceuticals, Inc.$355
  • Novartis$264
  • plus $908 from 12 others

What the payments were for

  • Speaking & faculty fees$27,15075%
  • Travel & lodging$4,10511%
  • Food & beverage$4,88713%
  • Education$180%
  • Gifts$1400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,300 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$224,516
Medicare patients
388
Services billed
1,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate158$85,848
CombiganBrimonidine Tartrate/Timolol96$35,880
LumiganBimatoprost70$34,637
RestasisCyclosporine31$31,708
Latanoprost1,344$22,692
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol84$14,635
Brimonidine Tartrate447$13,604
SimbrinzaBrinzolamide/Brimonidine Tart51$11,862
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat638$10,777
VyzultaLatanoprostene Bunod15$10,597
Difluprednate60$9,853
Travoprost40$8,760
RocklatanNetarsudil Mesylat/Latanoprost16$7,822
Alphagan PBrimonidine Tartrate22$6,744
Prednisolone Acetate129$6,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan, Restasis, Alphagan P$1,117$108,968219 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$355$93,670174 claims
AlconSimbrinza$720$11,86251 claims
Bausch & Lomb Americas Inc.Vyzulta$228$10,59715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →